 SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--Twist Bioscience Corporation Nasdaq: TWST today reported that its internally-discovered antibody candidate TB202-3 CoVIC-094, demonstrated potent binding to diverse SARS-CoV-2 variant mutations, including strains with the E484K, N501Y, D614G, Y453F and K417N mutations in pseudovirus assays, indicating this therapeutic antibody may be effective in treating many strains of COVID-19. The Coronavirus Immunotherapy Consortium CoVIC, an academic-ind 